Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Mallard Acquisition (MACUU)
MingZhu Logistics Holdings (YGMZ)
Good Works Acquisition (GWACU)
Bull Horn Holdings (BHSEU)
Decarbonization Plus Acquistion (DCRBU)
Horizon Acquisition II (HZON.U)
Helix Acquisition (HLXA)
Datto Holding Corp. (MSP)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Foghorn Therapeutics Inc. (FHTX)
Gatos Silver, Inc. (GATO)
Priced IPO
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
fuboTV Inc. (FUBO)
Presidio Property Trust (SQFT)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
C4 Therapeutics, Inc. (CCCC)
Oncorus, Inc (ONCR)
More companies

Graybug Vision, Inc. (GRAY)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Their novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes. Their lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are leading causes of retinal disease. They are developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME. In their Phase 1/2a clinical trial, GB-102 administered as a single 1 mg dose was well-tolerated in wet AMD patients and demonstrated durable clinical evidence of disease control of at least six months in approximately 88% of patients in this cohort. GB-102 is currently in a dose-ranging, controlled and masked safety and efficacy Phase 2b clinical trial in patients with wet AMD. They expect to report topline data from this trial in the first half of 2021.
Industry
Pharmaceuticals
CEO CFO
Frederic Guerard, Pharm.D. Robert S. Breuil
Employees Founded
4 2015

Contacts

Address: 275 Shoreline Drive, Suite 450 Redwood City, CA 94065

Telephone: (650) 487-2800

Web page: http://www.graybug.com

IPO information

Expected Date 9/25/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $306.56
Revenues (MM) $0
Net Income (Loss) (MM) $-43.6

Voting

What do you think will happen with the GRAY share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 4.7
Shares Revised (MM) 5.63
Expected offer amount (MM) $75.2
Realized offer amount(MM) $90
Underwriters
SVB Leerink/ Piper Sandler
CO-Managers
Needham/ Wedbush PacGrow

Sector: Healthcare

Tweets about $GRAY

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats